IMC.ASX: Immuron Travelan continued strong sales growth

Immuron Travelan continued strong sales growth

Stock	Immuron Ltd (IMC.ASX)
Release Time	17 Jan 2025, 10:29 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Immuron Travelan continued strong sales growth

Key Points

Global Travelan sales up 70% in Q4 2024 vs prior quarter, up 249% on pcp
Australia Travelan sales up 83% in Q4 2024 vs prior quarter, up 314% on pcp
North America Travelan sales up 43% in Q4 2024 vs prior quarter, up 141% on pcp

Full Summary

Immuron Limited, an Australian-based and globally integrated biopharmaceutical company, has announced continued strong sales growth (unaudited) of its over-the-counter immune supplement Travelan. In the December 2024 quarter, global Travelan sales increased by 70% to AUD$2.5 million compared to the prior quarter, and were up 249% year-on-year. In Australia, Travelan sales increased by 83% in the December 2024 quarter compared to the prior quarter, and were up 314% year-on-year. In North America, Travelan sales increased by 43% in the December 2024 quarter compared to the prior quarter, and were up 141% year-on-year. For the December 2024 half-year, global Travelan sales were AUD$4.0 million, up 70% on the prior corresponding period. In Australia, Travelan sales for the half-year were AUD$2.9 million, up 54% on the prior corresponding period. In North America, Travelan sales for the half-year were AUD$1.1 million, up 130% on the prior corresponding period.